SpinalCyte, LLC Announces Final Animal Trials for Spinal Disc Tissue Engineering

SpinalCyte, LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today an agreement between SpinalCyte and Howard An, M.D., The Morton International Endowed Chair Professor of Orthopaedic Surgery & Director, Division of Spine Surgery and Spine Fellowship Program, Rush University Medical Center to complete the final animal trials. The initial animal trials, using 16 rabbits, succeeded in regrowing the nucleus of the spinal disc and restoring disc height by over 80%. The resulting report was awarded the 2013 Best Science Award by ISASS (International Society for the Advancement of Spine Surgery). The final animal trial is scheduled to last 10 months and will increase the number of rabbits used to 64. It will also increase the in vivo monitoring by 8 weeks.

“We are excited about the additional scientific validation this will provide us prior to human studies,” said Pete O’Heeron, Chief Executive Officer. “Dr. An’s initial study at Rush University Medical Center proved that we have discovered a viable alternative to traditional treatment for degenerative disc disease (DDD) and the final animal trial should give us a full understanding of the human dermal fibroblasts’ interaction with the surrounding disc tissue.”

Read more...